Arie Belldegrun, MD
About Arie Belldegrun, MD
Arie Belldegrun, MD, is a prominent figure in the life sciences industry, serving as Founder, Chairman, President, and CEO of Kite Pharma. He has over 30 years of experience in academic research, company building, and collaborations with pharmaceutical companies.
Work at Kite Pharma
Arie Belldegrun serves as the Founder, Chairman, President, and CEO of Kite Pharma, Inc. since its establishment in 2009. Under his leadership, Kite Pharma has focused on developing innovative cancer therapies, particularly in the field of cell therapy. The company is recognized for its contributions to the advancement of CAR T-cell therapies, which have transformed treatment options for certain types of cancer. Belldegrun's role encompasses strategic direction, operational oversight, and fostering a culture of research and development within the organization.
Education and Expertise
Arie Belldegrun earned his Doctor of Medicine (MD) degree from Hadassah Medical School. He furthered his education with a Surgical Oncology Fellowship at the National Cancer Institute/NIH and completed a Urologic Surgery Residency at Harvard Medical School. His extensive academic training has equipped him with a deep understanding of oncology and urology, contributing to his expertise in the life sciences sector.
Background
With over 30 years of experience in the life sciences industry, Arie Belldegrun has built a career that spans academia, research, and business. He has held various leadership positions in multiple organizations, focusing on company building, research and development, and partnerships with pharmaceutical companies. His background includes significant contributions to academic research and collaborations that enhance the field of oncology.
Achievements
Arie Belldegrun has been instrumental in the establishment and growth of several biotechnology companies. He is currently involved with multiple organizations, including Allogene Therapeutics, ByHeart, IconOVir Bio, and Kronos Bio, Inc. His leadership roles extend to Ginkgo Bioworks, Inc. and Two River, where he serves as Chairman & Partner. Additionally, he has been a Professor and Director at UCLA Health System for over 30 years, emphasizing his commitment to education and research in urologic oncology.